MariTide is designed to combine the effects of glucagon-like peptide-1 (GLP-1) receptor activation with glucose-dependent ...

CHICAGO -- An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in ...

An experimental obesity drug has shown it can “substantially” reduce weight within a year, offering new hope for people with ...

A new experimental drug meant to be taken just once a month could lead to “substantial weight reduction” within a year and ...

Lead author of the study Ania Jastreboff is a professor at Yale School of Medicine and director of the Y-Weight Yale Obesity Research Centre. In a statement Professor Jastreboff said the team ...

Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...

New once-a-month drug could treat diabetes and obesity, scientists say. Researchers say experimental drug’s less frequent dosing could improve adherence and offer long-term control ...

Source Reference: Jastreboff AM, et al "Once-monthly maridebart cafraglutide for the treatment of obesity -- a phase 2 trial" N Engl J Med 2025; DOI: 10.1056/NEJMoa2504214.

Thousand Oaks, California Wednesday, June 25, 2025, 13:00 Hrs [IST] ...

A new experimental drug meant to be taken just once a month could lead to “substantial weight reduction” within a year and help overcome both diabetes and obesity, a new clinical trial suggests..

Alternatives to weekly injections of weight-loss drugs may be on the way. A monthly dose of a new drug called MariTide helped ...